| Name | Title | Contact Details |
|---|
BC Mental Health and Addiction Services is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Midwest Medical Staffing is a Overland Park, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fast Lane Mobile Advertising is a Dunkirk, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Campbell County Hospital District, doing business as Campbell County Memorial Hospital, operates as a community hospital that provides healthcare services serving patients and residents in Gillette. The company offers emergency medical services, behavioral health services, cancer care, outpatient services, emergency care, home medical care, occupational health services, first aid and CPR services, OB GYN services, audiology, internal medicine, infectious disease care, neurology and pain care, geriatric medicine, nephrology, pulmonary and sleep medicine, urology, home care services, laboratory services, nutritional care, radiology, rehabilitation services, hospice care, ICU services, orthopedics and spine care, surgery, maternal child care, powder river surgery, nursing, and health sciences education programs, as well as ear, nose, and throat care. It also provides dialysis, medical and radiation oncology, daycare, and inpatient services; and patient channel services, including heart diseases and strokes care, pain management, diabetes, breastfeeding, general health and wellness, and other services. In addition, the company offers services in the areas of children's healthcare, diet/exercise programs, mental healthcare, senior healthcare, women's health, pregnancy, workplace healthcare, health assessments, and men's healthcare. Campbell County Hospital District was founded in 1981 and is based in Gillette, Wyoming.
Telesta Therapeutics is a biopharmaceutical company focused on the development, manufacturing and commercialization of transformative human therapeutics. Our main focus is on novel medicines that address major unmet medical needs, particularly in oncology. Our anchor product, MCNA, has completed a Phase III pivotal study in patients with non-muscle invasive bladder cancer that have failed the first line therapy, bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application (BLA) for MCNA with the U.S. FDA on June 29, 2015 and is seeking, upon marketing approval in the U.S., to make MCNA available for patients and their physicians. Our ultimate goal is to transform the treatment landscape and prolong and improve the lives of those affected by bladder cancer, one of the most common types of cancers today.